What is Malin?
Malin Corporation plc, through its subsidiaries, operates within the dynamic life sciences industry, with a strategic focus on Ireland and the United States. The company is dedicated to addressing high unmet medical needs through the development of innovative cell and gene therapies. Its portfolio extends to medicines targeting cancer, infections, and autoimmune diseases, alongside specialized treatments for recurrent vulvovaginal candidiasis and fungal nail infections. Malin is also exploring novel approaches for protein misfolding diseases and developing advanced UV-light disinfection technologies. The company's diverse operations highlight its commitment to pioneering advancements across multiple therapeutic areas.
How much funding has Malin raised?
Malin has raised a total of $125.1M across 2 funding rounds:
Private Equity
$46.2M
Debt
$78.9M
Private Equity (2015): $46.2M, investors not publicly disclosed
Debt (2016): $78.9M led by European Investment Bank
Key Investors in Malin
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution, often supporting innovative and strategic projects within the EU and beyond.
What's next for Malin?
The recent major strategic investment in Malin signals a strong validation of its business model and therapeutic pipeline. This capital infusion is expected to accelerate the company's research and development efforts, potentially enabling faster clinical trials and market entry for its promising cell and gene therapies. Furthermore, the enterprise-level funding context suggests Malin is poised for significant scaling, possibly involving strategic partnerships or acquisitions to expand its global reach and impact in addressing critical health challenges. The company's focus on unmet medical needs positions it for sustained growth and influence within the life sciences landscape.
See full Malin company page
